Drug
GS 5319
GS 5319: highest development phase Phase 1, developed by Gilead Sciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| GS-5319 NCT07128303 | Phase 1 | Advanced Solid Tumor |
Latest
No recent events.
Follow GS 5319 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.